For example, the phase 2 NCT03071926 trial explores the outcomes of metronomic pegylated doxorubicin in endocrine-resistant advanced BC, while phase 2 NCT05747326 study checks 1-year performance free survival (PFS) of capecitabine and vinorelbine in HER-2 negative BC. This evidence concerns the gene ERBB2 and breast cancer.